Boehringer Ingelheim pads respiratory pipeline with somatotaxin buy
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has acquired global rights to a Phase II respiratory compound and a broader inflammation development programme focused on a novel class of small molecule anti-inflammatory compounds from UK firm Funxional Therapeutics.